Seminars in Nuclear Medicine
Volume 34, Issue 4 , Pages 293-299, October 2004

The role of positron emission tomography in radiation treatment planning

  • Steven Bujenovic, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to: Steven Bujenovic, MD, Nuclear Medicine Associates, LLC, 8241 Summa Ave, Suite D, Baton Rouge, LA 70809.

Department of Nuclear Medicine, Our Lady of the Lake, Regional Medical Center, Rouge, LA.

We estimate that 30% to 40% of radiation treatment plans for cancer patients are changed when positron emission tomography (PET) scan findings are factored into the plan. The most frequent changes are upstaging of disease and the finding of new distant metastases. When a tumor demonstrates high tracer uptake, the PET scan has high accuracy in staging and in determining recurrent disease. However, the absence of tracer uptake cannot exclude residual dormant disease. Following radiation therapy, a PET scan should be delayed at least 6 weeks and preferably 3 to 4 months so that inflammation within the radiation field can dissipate. PET has resulted in changes in the gross tumor volume; however, the process remains subjective.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0001-2998(04)00043-1

doi:10.1053/j.semnuclmed.2004.06.005

Seminars in Nuclear Medicine
Volume 34, Issue 4 , Pages 293-299, October 2004